| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 58,989 | 54,710 | ||
| General and administrative | 14,798 | 15,741 | ||
| Total operating expenses | 73,787 | 70,451 | ||
| Loss from operations | -73,787 | -70,451 | ||
| Interest and other income, net | 8,183 | 8,929 | ||
| Loss before provision for income taxes | -65,604 | -61,522 | ||
| Provision for income taxes | 108 | 139 | ||
| Net loss attributable to ordinary shareholders | -65,712 | -61,661 | ||
| Unrealized gain (loss) on investments, net | 463 | -453 | ||
| Total other comprehensive gain (loss) | 463 | -453 | ||
| Comprehensive loss | -65,249 | -62,114 | ||
| Earnings per share, basic | -0.37 | -0.36 | ||
| Earnings per share, diluted | -0.37 | - | ||
| Weighted average number of shares outstanding, basic | 175,469,000 | 172,647,000 | ||
| Weighted average number of shares outstanding, diluted | 175,469,000 | - | ||
Structure Therapeutics Inc. (GPCR)
Structure Therapeutics Inc. (GPCR)